Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience
Objective Antimicrotubular agents are among the most commonly used classes of chemotherapeutic agents, but the risk of cardiovascular adverse events (CVAEs) remains unclear. Our objective was to study the CVAEs associated with antimicrotubular agents.Methods The Food and Drug Administration’s Advers...
Saved in:
| Main Authors: | Avirup Guha, Sarju Ganatra, Brijesh Patel, Daniel Addison, Anita Deswal, Sherry-Ann Brown, Michael Fradley, Akshee Batra, Lauren A Baldassarre, Nihar Desai, Neal Weintraub, Zeeshan Hussain, Vivek Agarwala, Purvish M Parikh, Arjun Ghosh |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-12-01
|
| Series: | Open Heart |
| Online Access: | https://openheart.bmj.com/content/8/2/e001849.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
On the Vincas Trumpa model of 19th century Lithuanian history
by: Antanas Kulakauskas
Published: (1997-12-01) -
Biochemical synthesis of taxanes from mevalonate
by: Jing Li, et al.
Published: (2024-12-01) -
A Group Find of Neolithic Figurines of the Vinča Culture from Stubline, Serbia
by: Miloš Spasić
Published: (2014-12-01) -
HURP binding to the vinca domain of β-tubulin accounts for cancer drug resistance
by: Athira Saju, et al.
Published: (2024-10-01) -
Cancer nuclear envelope rupture and repair in taxane resistance
by: Xu Ana P., et al.
Published: (2024-12-01)